ArticlePloS one2017
Short-chain fatty acid receptors inhibit invasive phenotypes in breast cancer cells.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 120 citations in OpenAlex.
- Gut microbiome modulates breast cancer risk in socially isolated mice.Breast cancer research : BCR · 2026Article
- Differences in composition and diversity of the gut microbiota of post-menopausal breast cancer patients.Scientific reports · 2026Article
- Longitudinal multiomics analysis of endocrine therapy effects and gut microbiota in breast cancer recurrence.Communications medicine · 2026Article
- Obesity, chronic breast inflammation and carcinogenesis: Molecular pathways and clinical implications (Review).International journal of oncology · 2026Review
- Effects of Tumor-associatedArchives of Razi Institute · 2025Article
- Guardians in the Gut: Mechanistic Insights into a Hidden Ally Against Triple-Negative Breast Cancer.Cancers · 2025Review
- Combination strategies of gut microbiota in cancer therapy through metabolic reprogramming and immune remodeling.Cell communication and signaling : CCS · 2025Review
- G-protein coupled receptors in metabolic reprogramming and cancer.Pharmacology & therapeutics · 2025Review
- Bacterial metabolites: Effects on the development of breast cancer and therapeutic efficacy (Review).Oncology letters · 2025Review
- Endocrine-targeting therapies shift the breast microbiome to reduce estrogen receptor-α breast cancer risk.Cell reports. Medicine · 2025Article
- Faecalcrobiota metabolites: emerging insights into cancer radiotherapy outcomes.Frontiers in microbiology · 2025Review
- Sodium butyrate and sodium propionate inhibit breast cancer cell migration and invasion through regulation of epithelial-to-mesenchymal transition and suppression of MEK/ERK signaling pathway.Frontiers in cell and developmental biology · 2025Article
- Integrated analysis of microbiota and gut microbial metabolites in blood for breast cancer.mSystems · 2024Article
- Disentangling the molecular mystery of tumour-microbiota interactions: Microbial metabolites.Clinical and translational medicine · 2024Review
- Microbial metabolites affect tumor progression, immunity and therapy prediction by reshaping the tumor microenvironment (Review).International journal of oncology · 2024Review
- Potential antitumor effects of short-chain fatty acids in breast cancer models.American journal of cancer research · 2024Article
- The oral-gut microbiome axis in breast cancer: from basic research to therapeutic applications.Frontiers in cellular and infection microbiology · 2024Review
- Multi-omics-based investigation ofFrontiers in microbiology · 2024Article
- Propionate reinforces epithelial identity and reduces aggressiveness of lung carcinoma.EMBO molecular medicine · 2023Article
- The tremendous clinical potential of the microbiota in the treatment of breast cancer: the next frontier.Journal of cancer research and clinical oncology · 2023Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Short chain fatty acids (2 to 6 carbons in length) are ubiquitous lipids that are present in human plasma at micromolar concentrations. In addition to serving as metabolic precursors for lipid and carbohydrate synthesis, they also act as cognate ligands for two known G protein-coupled receptors (GPCRs), FFAR2 and FFAR3. While there is evidence that these receptors may inhibit the progression of colorectal cancer, their roles in breast cancer cells are largely unknown. We evaluated the effects of enforced overexpression of these receptors in two phenotypically distinct breast cancer cell lines: MCF7 and MDA-MD-231. Our results demonstrate that both receptors inhibit cell invasiveness, but through different signaling processes. In invasive, mesenchymal-like MDA-MB-231 cells, FFAR2 inhibits the Hippo-Yap pathway and increases expression of adhesion protein E-cadherin, while FFAR3 inhibits MAPK signaling. Both receptors have the net effect of reducing actin polymerization and invasion of cells through a Matrigel matrix. These effects were absent in the less invasive, epithelial-like MCF7 cells. Correspondingly, there is reduced expression of both receptors in invasive breast carcinoma and in aggressive triple-negative breast tumors, relative to normal breast tissue. Cumulatively, our data suggest that the activation of cognate receptors by short chain fatty acids drives breast cancer cells toward a non-invasive phenotype and therefore may inhibit metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.